The current financial score of Immunitybio Inc is 7.58. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 51.24M, representing a year-over-year increase of 93.91%, while its net profit experienced a year-over-year increase of 148.91%.
The current valuation score of Immunitybio Inc is 9.16. Its current P/E ratio is -9.98, which is -88.59% below the recent high of -1.14 and -190.03% above the recent low of -28.96.
The current earnings forecast score of Immunitybio Inc is 9.00. The average price target is 12.75, with a high of 15.00 and a low of 12.00.
The current price momentum score of Immunitybio Inc is 4.17. Currently, the stock price is trading between the resistance level at 9.06 and the support level at 7.65, making it suitable for range-bound swing trading.
The current institutional shareholding score of Immunitybio Inc is 3.00. The latest institutional shareholding proportion is 20.71%, representing a quarter-over-quarter increase of 32.91%.
The current risk assessment score of Immunitybio Inc is 5.22. The company's beta value is 0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.